XFOR X4 Pharmaceuticals, Inc: Net earnings per share for the last 12 months
X4 Pharmaceuticals relies on exclusive sales rights for Xolremdi, which guarantees stable demand due to a lack of alternatives. The business's success is based on insurance company support and the recognition of the therapy by specialists. The current earnings per share stand at 93.10, which is clearly demonstrated by the price chart on the GURU.Markets platform for this immune agent developer.
Financial and market metric breakdowns for X4 Pharmaceuticals, Inc. (XFOR)
- market value and analyst target forecast:
- company stock capitalization data:
- book capitalization data:
- debt burden and liquidity indicators:
Debt to Capital X4 Pharmaceuticals|XFOR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio X4 Pharmaceuticals Inc.|XFOR - Company Aggregate Debt|Debt to Book Value X4 Pharmaceuticals|XFOR - Company Long-Term Loans and Borrowings|Company Short-Term Debt X4 Pharmaceuticals|Quick Ratio x4pharma.com
- earnings and multiples data:
XFOR - Final Profit|Projected Future Earnings X4 Pharmaceuticals|XFOR - P/E Multiple|Future Price to Earnings X4 Pharmaceuticals, Inc|XFOR - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization X4 Pharmaceuticals|XFOR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) X4 Pharmaceuticals|XFOR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth x4pharma.com|XFOR - Net earnings per share growth this year|Earnings growth forecast for next year X4 Pharmaceuticals
- revenue and sales details:
Basic company analysis:X4 Pharmaceuticals
Fundamental asset screening requires an analysis of profit dynamics to distinguish stagnating companies from growth stocks. The 12-month YoY EPS growth rates, calculated using a rolling window of 10-K and 10-Q reports, neutralize one-time write-offs, reflecting the actual monetization efficiency of Xolremdi within the niche orphan disease market and the ability of X4 Pharmaceuticals (XFOR) to generate sustainable earnings per share.
Competitors of X4 Pharmaceuticals
argenx N.V. (ARGX) - Net earnings per share for the last 12 months|BioNTech Pharma (BNTX) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Abivax|Net earnings per share for the last 12 months ADMA|Net earnings per share (EPS TTM) protagonist-inc.com|Earnings per share for the last twelve months Immunovant Corp (IMVT)|Kiniksa - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRFS (grifols.com)|Adaptive Biotechnologies Corp (ADPT) - Net earnings per one share for the last twelve months|celldex.com - Net earnings per share (EPS TTM)|AUPH - Net earnings per share (EPS TTM)|BCRX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Vera Therapeutics Inc (VERA)|DNTH (Dianthus Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Pharvaris Pharma|Net earnings per share (EPS TTM) ABCL|TRML (tourmalinebio.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) PGEN (Precigen Inc)|PHAR - Net earnings per share for the last 12 months|NKTR - Earnings per share for the last twelve months|UPB - Net earnings per share (EPS TTM)|ZBIO: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Immunome, Inc.|Earnings per share for the last twelve months Gossamer Bio|Net earnings per share (EPS TTM) KalVista Pharmaceuticals Inc|Net earnings per share for the last 12 months SEPN (Septerna Corp)|PVLA (Pieris Pharmaceuticals Inc) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) SVRA (savarapharma.com)|Earnings per share for the trailing year RIGL|ANAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year ATXS (Astria Therapeutics, Inc.)|ENGN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months RAPT Therapeutics, Inc. (RAPT)|Earnings per share for the last twelve months aerovatetx.com|Net earnings per share (EPS TTM) aclaristx.com|Earnings per share for the last twelve months Kyverna Therapeutics (KYTX)|Net earnings per share for the last four quarters Tiziana Life Sciences Ltd|Net earnings per share (EPS TTM) CABA (Cabaletta Bio Inc)|VTYX: Earnings per share for the last 12 months|Theratechnologies, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Avalo Therapeutics, Inc AVTX|ELDN (Eledon Pharmaceuticals) - Net earnings per share for the last 12 months|Agenus Inc. - Earnings per share for the trailing year|Earnings per share for the last twelve months Climb Bio|Net earnings per share (EPS TTM) Zura Bio Ltd|Net earnings per share for the last 12 months ATYR (aTyr Pharma Inc)|Net earnings per share for the last four quarters Adagene Inc|Earnings per share for the last twelve months ImageneBio Inc IMA|Earnings per share for the last four quarters STTK (shattucklabs.com)|EQ: Net earnings per share for the last 12 months|CNTB: Earnings per share for the last twelve months|IMUX: Net earnings per share (EPS TTM)|Atara Biotherapeutics (ATRA) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months IFRX|Net earnings per share for the last 12 months adicetbio.com (ACET)|Earnings per share for the last twelve months Celularity Inc (CELU)|Net earnings per share for the last 12 months INmune Bio Corp INMB|Earnings per share for the last twelve months barinthusbio.com BRNS|Earnings per share for the trailing year KZR|sabbiotherapeutics.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year AKTX (Akari Therapeutics PLC)|ENLV: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months QTTB|GOVX (geovax.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Edesa Biotech|Net earnings per share (EPS TTM) IBIO|Net earnings per share for the last 12 months Carisma Therapeutics Inc. CARM|Earnings per share for the last twelve months XTL Biopharmaceuticals, Ltd. XTLB|Net earnings per share (EPS TTM) boltbio.com BOLT|HCWB - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Aptevo Therapeutics Inc. APVO|AIM ImmunoTech, Inc. (AIM) - Earnings per share for the last twelve months|ADTX: Earnings per share for the last four quarters|GRI (GRI Bio Corporation) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) XORTX Therapeutics Inc.|Earnings per share for the last twelve months Vyome Holdings (HIND)|Net earnings per share for the last four quarters revbiosciences.com|Earnings per share for the last twelve months Indaptus Therapeutics Inc INDP|Net earnings per share (EPS TTM) Scinai SCNI|CALI - Earnings per share for the last twelve months|Earnings per one share for the last 12 months AFMD|ALLK (Allakos Therapeutics) - Net earnings per share for the last 12 months|HOOKIPA - Earnings per share for the trailing year|IGMS (IGM Biosciences) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months iTeos Therapeutics Inc ITOS|Earnings per share for the last twelve months oceanbiomedical.com (OCEA)|Net earnings per share for the last 12 months TC Biopharm TCBP|Net earnings per share (EPS TTM) THRD (Third Harmonic Bio, Inc.)
